BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 22h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (19)
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Started Mar 2026
600 enrolled
Lupus Erythematosus, Systemic
A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis
Started Jan 2026
0Lupus Nephritis
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Started Jan 2026
115 enrolled
Myasthenia Gravis
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Started Feb 2025
50 enrolled
Thrombocytopenia, Neonatal Alloimmune
Nipocalimab in Moderate to Severe Sjogren's Disease
Started Dec 2024
655 enrolled
Sjogrens Syndrome
Worked on IMAAVY at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.